Preliminary results of this trial were promising; after six months of treatment, patients on metformin had significant improvements in body weight, glucose, insulin, leptin, and C-reactive protein [146] and reduced circulating levels of the cancer antigen 15-3 [147]. The gene discussed is INS; the disease is cancer.